1. Denton, CP, Khanna, D. Systemic sclerosis. Lancet 2017; 390: 1685–1699.
Google Scholar | Crossref | Medline2. Wollheim, FA. Classification of systemic sclerosis. Visions and reality. Rheumatology 2005; 44: 1212–1216.
Google Scholar | Crossref | Medline3. Akter, T, Silver, RM, Bogatkevich, GS. Recent advances in understanding the pathogenesis of scleroderma- interstitial lung disease. Curr Rheumatol Rep 2014; 16: 411.
Google Scholar | Crossref | Medline4. Bhattacharyya, S, Wei, J, Varga, J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2011; 8: 42–54.
Google Scholar | Crossref | Medline | ISI5. Spagnolo, P, Distler, O, Ryerson, CJ, et al. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Ann Rheum Dis 2021; 80: 143–150.
Google Scholar | Crossref | Medline6. Bouros, D, Wells, AU, Nicholson, AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581–1586.
Google Scholar | Crossref | Medline | ISI7. Jaeger, VK, Wirz, EG, Allanore, Y, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS One 2016; 11: e0163894.
Google Scholar | Crossref | Medline8. Nihtyanova, SI, Schreiber, BE, Ong, VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66: 1625–1635.
Google Scholar | Crossref | Medline9. Nihtyanova, SI, Denton, CP. Scleroderma lung involvement, autoantibodies, and outcome prediction: the confounding effect of time. J Rheumatology 2017; 44: 404–406.
Google Scholar | Crossref | Medline10. Winstone, TA, Assayag, D, Wilcox, PG, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 2014; 146: 422–436.
Google Scholar | Crossref | Medline11. Denton, CP, Wells, AU, Coghlan, JG. Major lung complications of systemic sclerosis. Nat Rev Rheumatol 2018; 14: 511–527.
Google Scholar | Crossref | Medline12. Hoffmann-Vold, AM, Molberg, Ø. Detection, screening, and classification of interstitial lung disease in patients with systemic sclerosis. Curr Opin Rheumatol 2020; 32: 497–504.
Google Scholar | Crossref | Medline13. Distler, O, Volkmann, ER, Hoffmann-Vold, AM, et al. Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease. Expert Rev Clin Immunol 2019; 15: 1009–1017.
Google Scholar | Crossref | Medline14. Goswami, RP, Ray, A, Chatterjee, M, et al. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. Rheumatology (Oxford) 2021; 60: 557–567.
Google Scholar | Crossref | Medline15. Walker, KM, Pope, J. Treatment of systemic sclerosis complications: what to use when first-line treatment fails-a consensus of systemic sclerosis experts. Semin Arthritis Rheum 2012; 42: 42–55.
Google Scholar | Crossref | Medline | ISI16. Fernández-Codina, A, Walker, KM, Pope, JE. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol 2018; 70: 1820–1828.
Google Scholar | Crossref | Medline17. Hoffmann-Vold, AM, Maher, TM, Philpot, EE, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol 2020; 2: e71–e83.
Google Scholar | Crossref18. Snowden, JA, Badoglio, M, Labopin, M, et al. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv 2017; 1: 2742–2755.
Google Scholar | Crossref | Medline19. Snowden, JA, Passweg, J, Moore, JJ, et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol 2004; 31: 482–488.
Google Scholar | Medline | ISI20. Spierings, J, van Laar, JM. Is there a place for hematopoietic stem cell transplantation in rheumatology? Rheum Dis Clin North Am 2019; 45: 399–416.
Google Scholar | Crossref | Medline21. Alexander, T, Greco, R, Snowden, JA. Hematopoietic stem cell transplantation for autoimmune disease. Ann Rev Med 2021; 72: 215–228.
Google Scholar | Crossref | Medline22. Puyade, M, Patel, A, Lim, YJ, et al. Autologous hematopoietic stem cell transplantation for Behçet’s disease: a retrospective survey of patients treated in Europe, on behalf of the autoimmune diseases working party of the European Society for Blood and Marrow Transplantation. Front Immunol 2021; 12: 638709.
Google Scholar | Crossref | Medline23. Alexander, T, Samuelson, C, Daikeler, T, et al. Autologous Haematopoietic Stem Cell Transplantation (HSCT) for Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis: a retrospective survey of patients reported to European Society for Blood and Marrow Transplantation (EBMT) registry. Bone Marrow Transplant 2020; 55: 1512–1515.
Google Scholar | Crossref | Medline24. Spierings, J, Van Rhijn-Brouwer, FCC, Van Laar, JM. Hematopoietic stem-cell transplantation in systemic sclerosis: an update. Curr Opin Rheumatol 2018; 30: 541–547.
Google Scholar | Crossref | Medline25. Henes, J, Oliveira, MC, Labopin, M, et al. Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. Haematologica 2021; 106: 375–383.
Google Scholar | Crossref | Medline26. Ayano, M, Tsukamoto, H, Mitoma, H, et al. CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I/II clinical trial conducted in Japan. Arthritis Res Ther 2019; 21: 30.
Google Scholar | Crossref | Medline27. Spierings, J, van Rhijn-Brouwer, FCC, de Bresser, CJM, et al. Treatment decision-making in diffuse cutaneous systemic sclerosis: a patient’s perspective. Rheumatology (Oxford) 2020; 59: 2052–2061.
Google Scholar | Crossref | Medline28. Burt, RK, Shah, SJ, Dill, K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378: 498–506.
Google Scholar | Crossref | Medline | ISI29. Van Laar, JM, Farge, D, Sont, JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490–2498.
Google Scholar | Crossref | Medline | ISI30. Sullivan, KM, Goldmuntz, EA, Keyes-Elstein, L. Autologous stem-cell transplantation for severe scleroderma. N Engl J Med 2018; 378: 1066–1067.
Google Scholar | Crossref | Medline31. Shouval, R, Furie, N, Raanani, P, et al. Autologous hematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis. Biol Blood Marrow Transplant 2018; 24: 937–944.
Google Scholar | Crossref | Medline32. Henrique-Neto, Á, Vasconcelos, MYK, Dias, JBE, et al. Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience. Adv Rheumatol 2021; 61: 9.
Google Scholar | Crossref | Medline33. Farge, D, Passweg, J, Van Laar, JM, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR registry. Ann Rheum Dis 2004; 63: 974–981.
Google Scholar | Crossref | Medline | ISI34. Nash, RA, McSweeney, PA, Crofford, LJ, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007; 110: 1388–1396.
Google Scholar | Crossref | Medline | ISI35. Del Papa, N, Onida, F, Zaccara, E, et al. Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis. Bone Marrow Transplant 2017; 52: 53–58.
Google Scholar | Crossref | Medline36. Goldin, J, Keyes-Elstein, L, Crofford, L, et al. Changes in quantitative scleroderma lung CT measures in patients treated with cyclophosphamide or transplantation. Arthritis Rheumatol 2018; 70(Suppl. 10): abstract 901.
Google Scholar37. van Bijnen, S, de Vries-Bouwstra, J, van den Ende, CH, et al. Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study. Ann Rheum Dis 2020; 79: 1084–1089.
Google Scholar | Crossref | Medline38. Goh, NS, Desai, SR, Veeraraghavan, S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248–1254.
Google Scholar | Crossref | Medline | ISI39. Ciaffi, J, van Leeuwen, NM, Boonstra, M, et al. Evolution of interstitial lung disease one year after hematopoietic stem cell transplantation or cyclophosphamide for systemic sclerosis. Arthritis Care Res (Hoboken) Epub ahead of print 22 September 2020. DOI: 10.1002/acr.24451.
Google Scholar | Crossref | Medline40. Kloth, C, Maximilian Thaiss, W, Preibsch, H, et al. Quantitative chest CT analysis in patients with systemic sclerosis before and after autologous stem cell transplantation: comparison of results with those of pulmonary function tests and clinical tests. Rheumatology (Oxford) 2016; 55: 1763–1770.
Google Scholar | Crossref | Medline41. Kloth, C, Henes, J, Xenitidis, T, et al. Chest CT texture analysis for response assessment in systemic sclerosis. Eur J Radiol 2018; 101: 50–58.
Google Scholar | Crossref | Medline42. Launay, D, Marjanovic, Z, De Bazelaire, C, et al. Autologous hematopoietic stem cell transplant in systemic sclerosis: quantitative high resolution computed tomography of the chest scoring. J Rheumatol 2009; 36: 1460–1463.
Google Scholar | Crossref | Medline43. Spierings, J, van Rhenen, A, Welsing, PM, et al. A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol. BMJ Open 2021; 11: e044483.
Google Scholar | Crossref | Medline44. Haider, S, Durairajan, N, Soubani, AO. Noninfectious pulmonary complications of haematopoietic stem cell transplantation. Eur Respir Rev 2020; 29: 1–18.
Google Scholar | Crossref45. Assassi, S, Wang, X, Chen, G, et al. Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures. Ann Rheum Dis 2019; 78: 1371–1378.
Google Scholar | Crossref | Medline46. Servaas, NH, Spierings, J, Pandit, A, et al. The role of innate immune cells in systemic sclerosis in the context of autologous hematopoietic stem cell transplantation. Clin Exp Immunol 2020; 201: 34–39.
Google Scholar | Crossref | Medline47. Michel, L, Farge, D, Baraut, J, et al. Evolution of serum cytokine profile after hematopoietic stem cell transplantation in systemic sclerosis patients. Bone Marrow Transplant 2016; 51: 1146–1149.
Google Scholar |